Hualan Biological Engineering (002007) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥1.65 billion, up 4.26% year-over-year, driven by stable blood products and new plasma station contributions.

• Net profit attributable to shareholders was ¥440 million, down 16.42% year-over-year, mainly due to lower vaccine sales and increased costs.

• Cash flow from operations decreased 58.13% year-over-year to ¥321 million, reflecting reduced cash receipts from sales and higher payments.

• The company maintained its leading position in blood products and influenza vaccines, with ongoing R&D in innovative drugs and biosimilars.

• No interim dividend, bonus shares, or capital increase from reserves for the half-year.

Financial highlights

• Operating income: ¥1.65 billion, up 4.26% year-over-year.

• Net profit attributable to shareholders: ¥440 million, down 16.42% year-over-year.

• Basic EPS: ¥0.2406, down 16.66% year-over-year.

• Gross margin for blood products: 50.10%, down 3.62 percentage points year-over-year.

• Cash and cash equivalents at period end: ¥2.03 billion.

Outlook and guidance

• Company expects continued growth in blood products through increased plasma collection and new station openings.

• Vaccine business faces pricing pressure but aims to offset with volume growth and cost control.

• R&D pipeline includes innovative vaccines and biosimilars, with several products in late-stage clinical trials or pending approval.